Antibody ELISA Kits for Tropical Infectious Disease Market Size to Hit USD 4.41 Billion by 2034

The global market for antibody ELISA kits used in diagnosing tropical infectious diseases is projected to grow from USD 2.39 billion in 2024 to USD 4.41 billion by 2034, representing a CAGR of 6.32% from 2025 to 2034. Asia Pacific dominates the market with a 33.2% revenue share in 2024 and is expected to grow at a CAGR of 6.51%, while the Middle East & Africa is projected to be the fastest-growing region. Key drivers include rising disease surveillance, public health investments, and the adoption of advanced diagnostic technologies such as AI-enhanced ELISA platforms. The dengue segment holds the largest market share by disease type, with the Zika virus segment expected to grow at the fastest rate. The IgM segment dominates by antibody type, while serum is the leading sample type. The diagnostic laboratories segment is the largest end user, and distributors/wholesalers dominate the distribution channel. Recent developments include new ELISA kits from InBios International, Agdia, and Panadea Diagnostics focused on improving accuracy and enabling point-of-care or field use, particularly in resource-limited settings.